Nicholas K Arger1, Brian O'Connor2, Laura L Koth1. 1. Division of Pulmonary and Critical Care, University of California, San Francisco, San Francisco, California. 2. National Jewish Health, Center for Genes, Environment, & Health, Denver, Colorado, USA.
Abstract
PURPOSE OF REVIEW: Sarcoidosis is a systemic disease characterized by granulomatous inflammation of unknown cause. There is extensive heterogeneity between patients with respect to the number and types of organs involved, disease course, and response to therapy. Recent research in the field has leveraged 'omics' techniques such as transcriptomics to identify important 'molecular profiles' in the disease. These tools may help in identifying clinically useful biomarkers and targets for therapy. RECENT FINDINGS: Several studies have used gene expression profiling of predesignated lists or the entire genome to find genes and markers that differentiate sarcoidosis from healthy controls, but only a few have compared sarcoidosis patients based on disease phenotypes and organ involvement. The common gene pathways that have been repeatedly identified include those related to the interferon response, T-cell receptor signaling, and the major histocompatibility complex. SUMMARY: While the molecular profiling studies to date offer the ability to compare sarcoidosis and health as well as across tissues, further longitudinal studies that include sarcoidosis patients with varying outcomes with respect to organ involvement and response to treatment are needed to identify clinically important phenotypes in the disease that can then be differentiated based on molecular features.
PURPOSE OF REVIEW: Sarcoidosis is a systemic disease characterized by granulomatous inflammation of unknown cause. There is extensive heterogeneity between patients with respect to the number and types of organs involved, disease course, and response to therapy. Recent research in the field has leveraged 'omics' techniques such as transcriptomics to identify important 'molecular profiles' in the disease. These tools may help in identifying clinically useful biomarkers and targets for therapy. RECENT FINDINGS: Several studies have used gene expression profiling of predesignated lists or the entire genome to find genes and markers that differentiate sarcoidosis from healthy controls, but only a few have compared sarcoidosispatients based on disease phenotypes and organ involvement. The common gene pathways that have been repeatedly identified include those related to the interferon response, T-cell receptor signaling, and the major histocompatibility complex. SUMMARY: While the molecular profiling studies to date offer the ability to compare sarcoidosis and health as well as across tissues, further longitudinal studies that include sarcoidosispatients with varying outcomes with respect to organ involvement and response to treatment are needed to identify clinically important phenotypes in the disease that can then be differentiated based on molecular features.
Authors: Bryan S Benn; Zoe Lehman; Sharon A Kidd; Melissa Ho; Sara Sun; Joris Ramstein; Nicholas K Arger; Christine P Nguyen; Robert Su; Antonio Gomez; Jeffrey M Gelfand; Laura L Koth Journal: Lung Date: 2017-07-13 Impact factor: 2.584
Authors: T Hoshino; R Suzuki; Y Tsuruta; T Matsutani; M Kikuchi; M Kawamoto; R Gouhara; T Shiraishi; M Mochizuki; K Itoh; K Oizumi Journal: Clin Exp Immunol Date: 1997-06 Impact factor: 4.330
Authors: Prescott G Woodruff; Homer A Boushey; Gregory M Dolganov; Chris S Barker; Yee Hwa Yang; Samantha Donnelly; Almut Ellwanger; Sukhvinder S Sidhu; Trang P Dao-Pick; Carlos Pantoja; David J Erle; Keith R Yamamoto; John V Fahy Journal: Proc Natl Acad Sci U S A Date: 2007-09-26 Impact factor: 11.205
Authors: Shamila D Alipoor; Ian M Adcock; Johan Garssen; Esmaeil Mortaz; Mohammad Varahram; Mehdi Mirsaeidi; Aliakbar Velayati Journal: Eur J Pharmacol Date: 2016-09-12 Impact factor: 4.432
Authors: Christian Garzoni; Silvio D Brugger; Weihong Qi; Sarah Wasmer; Alexia Cusini; Philippe Dumont; Meri Gorgievski-Hrisoho; Kathrin Mühlemann; Christophe von Garnier; Markus Hilty Journal: Thorax Date: 2013-08-14 Impact factor: 9.139